Pricing Log in Create free account
Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%
Market cap
$82.0B
P/E
18.9×
Fwd P/E
16.5×
Dividend yield
0.47%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a EV/FCF of 21.5×. Over the past ten years it has ranged from −1,854× (August 2015) to 255× (June 2015); the current reading is higher than 37% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 20.3× 0.15%
FY2024 20.2× (17.43%)
FY2023 24.5× 13.16%
FY2022 21.7× 119.20%
FY2021 9.9× (62.35%)
FY2020 26.2× 36.38%
FY2019 19.2× (8.70%)
FY2018 21.1× (45.43%)
FY2017 38.6× (3.69%)
FY2016 40.1× (52.62%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 16.7× (15.85%)
Mar 2026 19.8× (2.31%)
Dec 2025 20.3× 45.68%
Sep 2025 13.9× (4.66%)
42 more quarters

Against its own ten years

Low −1,854× High 255×
Ten-year median 25.0×
Current reading's percentile 38

EV/FCF against peers

Company EV/FCF
MRNA Moderna, Inc. compare −66.1×
RVMD Revolution Medicines, Inc. compare −28.1×
ROIV Roivant Sciences Ltd. compare −25.1×
REGN Regeneron Pharmaceuticals, Inc. 21.5×
RPRX Royalty Pharma PLC compare 27.0×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 28.5×
VRTX Vertex Pharmaceuticals Incorporated compare 31.4×
ARGX argenex SE compare 34.4×
ALNY Alnylam Pharmaceuticals, Inc. compare 35.0×

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on REGN